A 15-year-old boy with refractory juvenile rheumatoid arthritis (JRA) underwent intense immunosuppressive therapy followed by purified blood CD34
steroidal anti-inflammatory drugs (NSAIDs) or immunosuppressive drugs such as methotrexate (MTX), cyclophosphamide (CY), and corticosteroids. In such cases, patients are susceptible to severe joint destruction and various adverse effects from long-term treatment, and adolescent patients often must endure a mental and physical burden. 3 To improve the quality of life in these patients, a new strategy with intense immunosuppression followed by stem cell support has been introduced, first for patients with fatal autoimmune disease, and then for those with non-fatal disease that is refractory to ordinary therapies. [4] [5] [6] [7] We report here a 15 year-old boy with refractory JRA who was treated with high-dose CY and anti-lymphocyte globulin (ALG) followed by purified blood CD34 + cell autografting.
Case report
The patient was a 15-year-old boy. In October 1992, at the age of 8, he developed high-grade fever and multiple arthralgia. Since his symptoms failed to respond to antibiotics prescribed by a general practitioner, he was referred to the Department of Pediatrics of Tokushima Municipal Hospital. The laboratory examinations revealed acceleration of the erythrocyte sedimentation rate (102 mm/h) and elevation of C-reactive protein (14.5 mg/dl) and the serum ferritin value (1200 mg/dl). Anti-nuclear antigen was negative and serum complement values were within the normal range. All cultures were negative, including bacteria and viruses. Antibody titers for parvovirus were negative, and parvovirus DNA was not detected in his blood. He was admitted to the hospital with a tentative diagnosis of JRA (Still type). After the admission, the disease could not be stabilized completely despite the administration of immunosuppressive agents and NSAIDs. The disease had relapsed seven times, whenever the dose of prednisolone (PDN) decreased to 20 mg/day, and myocarditis and pericarditis had developed during this time. Each time, the dose of PDN was increased to 60 mg/m 2 /day. Due to long-term administration of these drugs, he suffered from cataracts, kidney stones, delayed sexual maturation, and a short stature. He also suffered from psychological complications, as reflected by poor school attendance and socialization. Since his short stature (height Ͻ4 s.d. for age) and growth retar-dation (growth velocity Ͻ1.5 cm/year) were remarkable, recombinant human growth hormone (rGH; 0.5 IU/kg/week divided into six equal daily doses) was injected subcutaneously beginning in March 1998, when his bone age was 12 years. He was transferred to our University Hospital to discontinue the medication in order to overcome impaired physical growth and psychological disorders. On admission, he showed cushingoid facial features, was 144.2 cm tall (−4.1 s.d.), which was 23 cm less than the average for his age, and weighed 50 kg (−0.6 s.d.). He was not febrile with 20 mg of PDN every other day and a low dose of methotrexate (MTX; 1.8 mg/m 2 /week as a single dose). The extremities were symmetrical without pain, and there was no deformity of the joints. Findings for the heart and lung were within normal limits. Hirsutism and mild cataract were noted. His penis was small and infantile, pubic hair was absent, and the testes had a volume of ca. 1.0 cc. His bone age was 13 years and 5 months (chronological age 15 years and 7 months). The epiphysial line was not closed.
The details of the procedure were fully explained to the patient and his parents, and informed consent was obtained. Before starting the mobilization and harvesting protocol, he stopped taking MTX and the dose of PDN started to be tapered, although there was a concern regarding macrophage activation at the time of granulocyte colony-stimulating factor (G-CSF)-induced peripheral blood stem cell (PBSC) mobilization. 8 PBSC were mobilized according to our previously reported protocol. 9 Briefly, 10 g/kg of G-CSF (filgrastim; Kirin Brewery Co., Tokyo, Japan) was administered subcutaneously for 5 days. On days 5 and 6, PBSC were harvested using a CS-3000 plus (Baxter Healthcare, Deerfield, IL, USA) as reported.
10 CD34 + cells were purified in bulk from PBSC using an Isolex 300 (Baxter Healthcare, Irvine, CA, USA), which included anti-CD34 monoclonal antibody (9C5) and immunomagnetic beads (Dynabeads; Dynal, Oslo, Norway). The details of the harvesting and purification efficacy of CD34 + cells are shown in Table 1 . He again developed severe lumbago, multiple joint pain and high-grade fever while receiving 10 mg of PDN just before treatment. Since these symptoms are often seen in the recurrence of JRA, he was diagnosed as having his 8th relapse of JRA. After approval of the ethics committee was obtained, immunosuppressive therapy was started on 21 July 1999. The details of the immunosuppressive therapy are also shown in Table 1 . The administration of ALG (Lymphoglobulin; Merieux, Lyon, France) was planned for 4 days, but discontinued on day −2 because of severe allergic side-effects. Arthralgia, lumbago, and high-grade fever subsided quickly after the start of immunosuppressive therapy. A total of 3.6 × 10 /l on day 11. One month after transplant, he developed generalized itchiness and eruptions diagnosed as eosinophilic folliculitis, which was treated with antipruritic drugs. Eosinophilia (Ͼ35% of peripheral WBC) and atopic dermatitis in the extremities developed on day 60, but all symptoms disappeared without treatment. He has not received any immunosuppressive drugs after this treatment for 15 months. He was taking rGH injections. At 15 months after treatment, he had grown at a velocity of 16 cm/year, in contrast to the gain of 2 cm/year in the preceding 3 years (Figure 1 ). Although he was depressed after the treatment due to generalized itchy skin and loss of hair, his rapid growth has raised his spirits and improved his attendance at school.
Discussion
JRA is one of the most common rheumatic diseases of children under 16 years of age. 1 It is characterized by idiopathic synovitis of the peripheral joints, associated with soft-tissue swelling and effusion. Although the etiology is unknown, previous studies have suggested that excessive immune reactivity of several types of cells can be found in predisposed children, and that T cell activation results in a cascade of events leading to tissue damage in the joints and other affected tissues. 2 Children with JRA are usually treated with a combination of NSAIDs, disease-modifying anti-rheumatic drugs (DMARDs), and immunosuppressive drugs such as MTX and CPA. However, a few children do not respond to these non-steroidal drugs, and are often put on corticosteroids. Corticosteroids are very powerful antiinflammatory drugs, but carry a risk of severe adverse effects. They often have a prolonged course, accompanied by growth retardation, which has a psychological influence on adolescents. 3, 11, 12 Although rGH therapy is attempted, only a few reports have stated that rGH injection is effective for treating growth retardation in children with severe JRA. 13 Furthermore, rGH therapy was shown to be ineffective in a patient taking corticosteroids (PDN Ͼ0.35 mg/kg per day). 14 Autografting with purified or unmanipulated blood stem/progenitor cells has been tried as a possible treatment for patients with severe autoimmune disease. [4] [5] [6] [7] The European League against Rheumatism (EULAR) and European Group for Blood and Marrow Transplantation (EBMT) have published guidelines on inclusion criteria, conditioning regimen, and manipulation of the graft. 15 We followed the EULAR/EBMT guidelines, but did not include lowdose total body irradiation, considering its adverse effect on growth and sexual maturation and the risk of solid tumors later in life. The pros and cons of this treatment modality have been discussed in the literature. [16] [17] [18] [19] The rationale for autologous stem cell transplantation suggests that this intervention might 'reset the thermostat' so that normal immunoregulation can control the disease. It has been shown that severe immunosuppression may continue for several years after autografting, and affect the disease course. 5, 6 True cures might be very difficult to obtain by this approach, and corticosteroid-free remission and a general lowering of the autoimmune potential might be more realistic goals. For 15 months after transplant, our patient did not receive any immunosuppressive drugs, and showed catch-up growth. So far, this treatment modality has been Age (Years) Figure 1 Cross-sectional growth chart for a Japanese boy (0-18 years). rGH, recombinant human growth hormone; PBSCT, peripheral blood stem cell transplantation. Severe growth retardation had been noted from the onset of JRA. rGH injection enhanced catch-up growth, but the rate of catch-up growth greatly accelerated after PBSCT.
Bone Marrow Transplantation successful, although the durability of this remission is unknown. To obtain the benefit of rGH injection, the patient should stop taking corticosteroids to enable catch-up growth. Thus, a prolonged PDN-free period is essential for the expected rapid growth. Few JRA patients have been treated with purified CD34 + cell autografting and the follow-up duration is too short to draw any definite conclusions. 7 If patients suffering from this non-lethal disorder are carefully selected, intense immunosuppression followed by stem cell support might be acceptable for adolescent patients with refractory autoimmune diseases to achieve a drug-free period to allow for physical and psychological maturation.
